-
CD22 CAR LBCL Supplement, Blood 2021
Baird et al, Blood 2021
-
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 Car T-Cell Trial
Shah et al, Journal of Clinical Oncology 2021
-
Outcomes of Patients With Large B-Cell Lymphoma Progressing After Axicabtagene Ciloleucel Therapy
Spiegel et al, Blood 2021
-
LBCL Outcome Post CD19 Appendix
Spiegel et al, Blood 2021
-
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR T Immunotherapies
Parker et al, Cell Press 2020
Publications
CARGO is advancing a pipeline
of transformational next-generation
CAR T-cell therapies for cancer
